Bone cell interactions through Eph/ephrin: Bone modeling, remodeling and associated diseases

Cell Adhesion and Migration

Volumn 6, Issue 2, 2012, Pages 148-156

  Matsuo, Koichi ^a   Otaki, Natsuko ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cell cell interaction; Chondrocyte; Coupling factor; Coupling inhibitor; Multiple myeloma; Osteoarthritis; Osteoblast; Osteoclast; Osteosarcoma; Rheumatoid arthritis

Indexed keywords

COLLAGENASE 3; COLONY STIMULATING FACTOR 1; EPHRIN; EPHRIN A1; EPHRIN A2; EPHRIN B1; EPHRIN B2; EPHRIN B4; EPHRIN RECEPTOR B1; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PROTEIN C FOS; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA13; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

BONE CELL; BONE MINERALIZATION; BONE REMODELING; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CHONDROSARCOMA; CRANIOFACIAL MALFORMATION; CRANIOFRONTONASAL SYNDROME; DENTAL PLULP STEM CELL; ENCHONDRAL OSSIFICATION; HUMAN; LIMB DEVELOPMENT; LOSS OF FUNCTION MUTATION; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; POLYDACTYLY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOMITE; STEM CELL; TOOTH PULP;

MUS;

EID: 84863893647     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.20888     Document Type: Review

References (93)

1. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133:38-52; PMID:18394988; http://dx.doi.org/10.1016/j.cell. 2008.03.011.
2. Pitulescu ME, Adams RH. Eph/ephrin molecules-a hub for signaling and endocytosis. Genes Dev 2010; 24:2480-92; PMID:21078817; http://dx.doi.org/10. 1101/gad.1973910.
3. Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol 2007; 17:230-8; PMID:17420126; http://dx.doi.org/10.1016/j. tcb.2007.03.004.
4. Davy A, Soriano P. Ephrin signaling in vivo: look both ways. Dev Dyn 2005; 232:1-10; PMID:15580616; http://dx.doi.org/10.1002/dvdy.20200.
5. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10:165-80; PMID:20179713; http://dx.doi.org/10.1038/nrc2806.
6. Arthur A, Zannettino A, Panagopoulos R, Koblar SA, Sims NA, Stylianou C, et al. EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone 2011; 48:533-42; PMID:21056708; http://dx.doi.org/10.1016/j.bone.2010.10.180.
7. Stokowski A, Shi S, Sun T, Bartold PM, Koblar SA, Gronthos S. EphB/ephrin-B interaction mediates adult stem cell attachment, spreading, and migration: implications for dental tissue repair. Stem Cells 2007; 25:156-64; PMID:17204606; http://dx.doi.org/10.1634/stemcells.2006-0373.
8. Chal J, Pourquié O. Patterning and Differentiation of the Vertebrate Spine. In: Pourquié O, ed. The Skeletal System. New York: Cold Spring Harbor Laboratory Press, 2009:41-116.
9. Yasuhiko Y, Haraguchi S, Kitajima S, Takahashi Y, Kanno J, Saga Y. Tbx6-mediated Notch signaling controls somite-specific Mesp2 expression. Proc Natl Acad Sci U S A 2006; 103:3651-6; PMID:16505380; http://dx.doi.org/10.1073/ pnas.0508238103.
10. Morimoto M, Takahashi Y, Endo M, Saga Y. The Mesp2 transcription factor establishes segmental borders by suppressing Notch activity. Nature 2005; 435:354-9; PMID:15902259; http://dx.doi.org/10.1038/nature03591.
11. Nakajima Y, Morimoto M, Takahashi Y, Koseki H, Saga Y. Identification of Epha4 enhancer required for segmental expression and the regulation by Mesp2. Development 2006; 133:2517-25; PMID:16728472; http://dx.doi.org/10.1242/dev. 02422.
12. Barrios A, Poole RJ, Durbin L, Brennan C, Holder N, Wilson SW. Eph/Ephrin signaling regulates the mesenchymal-to-epithelial transition of the paraxial mesoderm during somite morphogenesis. Curr Biol 2003; 13:1571-82; PMID:13678588; http://dx.doi.org/10.1016/j.cub.2003.08.030.
13. Watanabe T, Sato Y, Saito D, Tadokoro R, Takahashi Y. EphrinB2 coordinates the formation of a morphological boundary and cell epithelialization during somite segmentation. Proc Natl Acad Sci U S A 2009; 106:7467-72; PMID:19380726; http://dx.doi.org/10.1073/pnas.0902859106.
14. Kullander K, Mather NK, Diella F, Dottori M, Boyd AW, Klein R. Kinase-dependent and kinase-independent functions of EphA4 receptors in major axon tract formation in vivo. Neuron 2001; 29:73-84; PMID:11182082; http://dx.doi.org/10.1016/S0896-6273(01)00181-7.
15. Twigg SR, Kan R, Babbs C, Bochukova EG, Robertson SP, Wall SA, et al. Mutations of ephrin-B1 (EFNB1), a marker of tissue boundary formation, cause craniofrontonasal syndrome. Proc Natl Acad Sci U S A 2004; 101:8652-7; PMID:15166289; http://dx.doi.org/10.1073/pnas.0402819101.
16. Wieland I, Jakubiczka S, Muschke P, Cohen M, Thiele H, Gerlach KL, et al. Mutations of the ephrin-B1 gene cause craniofrontonasal syndrome. Am J Hum Genet 2004; 74:1209-15; PMID:15124102; http://dx.doi.org/10.1086/421532.
17. Zafeiriou DI, Pavlidou EL, Vargìami E. Diverse clinical and genetic aspects of craniofrontonasal syndrome. Pediatr Neurol 2011; 44:83-7; PMID:21215906; http://dx.doi.org/10.1016/j.pediatrneurol.2010.10.012.
18. Compagni A, Logan M, Klein R, Adams RH. Control of skeletal patterning by ephrinB1-EphB interactions. Dev Cell 2003; 5:217-30; PMID:12919674; http://dx.doi.org/10.1016/S1534-5807(03)00198-9.
19. Orioli D, Henkemeyer M, Lemke G, Klein R, Pawson T. Sek4 and Nuk receptors cooperate in guidance of commissural axons and in palate formation. EMBO J 1996; 15:6035-49; PMID:8947026.
20. Risley M, Garrod D, Henkemeyer M, McLean W. EphB2 and EphB3 forward signalling are required for palate development. Mech Dev 2009; 126:230-9; PMID:19032981; http://dx.doi.org/10.1016/j.mod.2008.10.009.
21. Bush JO, Soriano P. Ephrin-B1 forward signaling regulates craniofacial morphogenesis by controlling cell proliferation across Eph-ephrin boundaries. Genes Dev 2010; 24:2068-80; PMID:20844017; http://dx.doi.org/10.1101/gad. 1963210.
22. Johnson D, Wilkie AO. Craniosynostosis. Eur J Hum Genet 2011; 19:369-76; PMID:21248745; http://dx.doi.org/10.1038/ejhg.2010.235.
23. Wieacker P, Wieland I. Clinical and genetic aspects of craniofrontonasal syndrome: towards resolving a genetic paradox. Mol Genet Metab 2005; 86:110-6; PMID:16143553; http://dx.doi.org/10.1016/j.ymgme.2005.07.017.
24. Davy A, Bush JO, Soriano P. Inhibition of gap junction communication at ectopic Eph/ephrin boundaries underlies craniofrontonasal syndrome. PLoS Biol 2006; 4:e315; PMID:16968134; http://dx.doi.org/10.1371/journal.pbio.0040315.
25. Xing W, Kim J, Wergedal J, Chen ST, Mohan S. Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1. Mol Cell Biol 2010; 30:711-21; PMID:19995908; http://dx.doi.org/10.1128/MCB.00610-09.
26. Davy A, Aubin J, Soriano P. Ephrin-B1 forward and reverse signaling are required during mouse development. Genes Dev 2004; 18:572-83; PMID:15037550; http://dx.doi.org/10.1101/gad.1171704.
27. Stadler HS, Higgins KM, Capecchi MR. Loss of Ephreceptor expression correlates with loss of cell adhesion and chondrogenic capacity in Hoxa13 mutant limbs. Development 2001; 128:4177-88; PMID:11684655.
28. Patel K, Nittenberg R, D'Souza D, Irving C, Burt D, Wilkinson DG, et al. Expression and regulation of Cek-8, a cell to cell signalling receptor in developing chick limb buds. Development 1996; 122:1147-55; PMID:8620841.
29. Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 2012; 13:27-38; PMID:22189423; http://dx.doi.org/10.1038/nrm3254.
30. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26:229-38; PMID:21254230; http://dx.doi.org/10.1002/jbmr.320.
31. Edwards JR, Mundy GR. Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 2011; 7:235-43; PMID:21386794; http://dx.doi.org/10.1038/nrrheum.2011.23.
32. Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004; 279:26475-80; PMID:15073183; http://dx.doi.org/10.1074/jbc.M313973200.
33. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3:889-901; PMID:12479813; http://dx.doi.org/10.1016/S1534-5807(02)00369-6.
34. Sims NA. EPHs and Ephrins: Many Pathways to Regulate Osteoblasts and Osteoclasts. IBMS BoneKEy 2010; 7:304-13; http://dx.doi.org/10.1138/20100463.
35. Kuroda C, Kubota S, Kawata K, Aoyama E, Sumiyoshi K, Oka M, et al. Distribution, gene expression, and functional role of EphA4 during ossification. Biochem Biophys Res Commun 2008; 374:22-7; PMID:18601903; http://dx.doi.org/10. 1016/j.bbrc.2008.06.089.
36. Kwan Tat S, Pelletier JP, Amiable N, Boileau C, Lavigne M, Martel-Pelletier J. Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes. Arthritis Res Ther 2009; 11:R119; PMID:19664212; http://dx.doi.org/10.1186/ar2782.
37. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006; 4:111-21; PMID:16890539; http://dx.doi.org/10.1016/j.cmet.2006.05.012.
38. Irie N, Takada Y, Watanabe Y, Matsuzaki Y, Naruse C, Asano M, et al. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J Biol Chem 2009; 284:14637-44; PMID:19299512; http://dx.doi.org/10.1074/jbc.M807598200.
39. Cheng S, Zhao SL, Nelson B, Kesavan C, Qin X, Wergedal J, et al. Targeted disruption of ephrin B1 in cells of myeloid lineage increases osteoclast differentiation and bone resorption in mice. PLoS One 2012; 7:e32887; PMID:22403721; http://dx.doi.org/10.1371/journal.pone.0032887.
40. Allan EH, Häusler KD, Wei T, Gooi JH, Quinn JM, Crimeen-Irwin B, et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 2008; 23:1170-81; PMID:18627264; http://dx.doi.org/10.1359/jbmr.080324.
41. Lamont RE, Childs S. MAPping out arteries and veins. Sci STKE 2006; 2006:pe39.
42. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998; 93:741-53; PMID:9630219; http://dx.doi.org/10.1016/ S0092-8674(00)81436-1.
43. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999; 13:295-306; PMID:9990854; http://dx.doi.org/10. 1101/gad.13.3.295.
44. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999; 4:403-14; PMID:10518221; http://dx.doi.org/10.1016/S1097-2765(00)80342-1.
45. Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, Mackem S, et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell 2010; 19:329-44; PMID:20708594; http://dx.doi.org/10.1016/j.devcel.2010.07.010.
46. Korff T, Dandekar G, Pfaff D, Füller T, Goettsch W, Morawietz H, et al. Endothelial ephrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31. Arterioscler Thromb Vasc Biol 2006; 26:468-74; PMID:16357318; http://dx.doi.org/10.1161/01.ATV.0000200081.42064.e7.
47. Pfaff D, Héroult M, Riedel M, Reiss Y, Kirmse R, Ludwig T, et al. Involvement of endothelial ephrin-B2 in adhesion and transmigration of EphB-receptor-expressing monocytes. J Cell Sci 2008; 121:3842-50; PMID:18957513; http://dx.doi.org/10.1242/jcs.030627.
48. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, et al. Localization of RANKL (receptor activator of NFkB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999; 25:525-34; PMID:10574572; http://dx.doi.org/10.1016/S8756-3282(99)00214-8.
49. Silvestrini G, Ballanti P, Patacchioli F, Leopizzi M, Gualtieri N, Monnazzi P, et al. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol 2005; 36:59-67; PMID:15704000; http://dx.doi.org/10.1007/s10735-004-3839-1.
50. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010; 465:483-6; PMID:20445537; http://dx.doi.org/10.1038/nature09002.
51. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010; 465:487-91; PMID:20445540; http://dx.doi.org/10.1038/ nature08995.
52. Kanzaki S, Takada Y, Niida S, Takeda Y, Udagawa N, Ogawa K, et al. Impaired vibration of auditory ossicles in osteopetrotic mice. Am J Pathol 2011; 178:1270-8; PMID:21356377; http://dx.doi.org/10.1016/j.ajpath.2010.11.063.
53. Grigoriadis AE, Schellander K, Wang ZQ, Wagner EF. Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 1993; 122:685-701; PMID:8335693; http://dx.doi.org/10.1083/jcb.122.3.685.
54. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 2000; 24:184-7; PMID:10655067; http://dx.doi.org/10.1038/72855.
55. Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett 2009; 583:2435-40; PMID:19576893; http://dx.doi.org/10.1016/j.febslet.2009.06.047.
56. Mäkinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, Alitalo K, et al. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 2005; 19:397-410; PMID:15687262; http://dx.doi.org/10. 1101/gad.330105.
57. Mao Y, Huang X, Zhao J, Gu Z. Preliminary identification of potential PDZ-domain proteins downstream of ephrin B2 during osteoclast differentiation of RAW264.7 cells. Int J Mol Med 2011; 27:669-77; PMID:21373749.
58. Pierroz DD, Rufo A, Bianchi EN, Glatt V, Capulli M, Rucci N, et al. b-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res 2009; 24:775-84; PMID:19113915; http://dx.doi.org/10.1359/jbmr.081237.
59. Harris WH, Heaney RP. Skeletal renewal and metabolic bone disease. N Engl J Med 1969; 280:253-9; PMID:4883109; http://dx.doi.org/10.1056/ NEJM196901302800507.
60. Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 1965; 206:489-90; PMID:5319106; http://dx.doi.org/10.1038/206489a0.
61. Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 2010; 11:219-27; PMID:21188536; http://dx.doi.org/10.1007/s11154-010- 9153-1.
62. Martin TJ, Sims NA, Quinn JMW. Interactions among osteoblasts, osteoclasts, and other cells in bone. In: Lorenzo J, Choi Y, Horowitz M, Takayanagi H, eds. Osteoimmunology: Interactions of the immune and skelatal systems: Elsevier, 2011:227-67.
63. Sims NA, Gooi JH. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008; 19:444-51; PMID:18718546; http://dx.doi.org/10.1016/j.semcdb.2008.07.016.
64. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communication on and within bone controls bone remodeling. Bone 2009; 44:1026-33; PMID:19345750; http://dx.doi.org/10.1016/j.bone.2009.03.671.
65. Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, Quinn JM, et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res 2008; 23:2025-32; PMID:18665789; http://dx.doi.org/10.1359/jbmr.080706.
66. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A 2008; 105:20764-9; PMID:19075223; http://dx.doi.org/10.1073/pnas.0805133106.
67. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, et al. TGF-b1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15:757-65; PMID:19584867; http://dx.doi.org/10.1038/nm.1979.
68. Guaiquil VH, Swendeman S, Zhou W, Guaiquil P, Weskamp G, Bartsch JW, et al. ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J Mol Med (Berl) 2010; 88:497-505; PMID:20119708; http://dx.doi.org/10.1007/s00109-010-0591-8.
69. Mundy GR, Elefteriou F. Boning up on ephrin signaling. Cell 2006; 126:441-3; PMID:16901775; http://dx.doi.org/10.1016/j.cell.2006.07.015.
70. Tran Van PT, Vignery A, Baron R. Cellular kinetics of the bone remodeling sequence in the rat. Anat Rec 1982; 202:445-51; PMID:7072987; http://dx.doi.org/10.1002/ar.1092020403.
71. Vignery A, Baron R. Dynamic histomorphometry of alveolar bone remodeling in the adult rat. Anat Rec 1980; 196:191-200; PMID:7416512; http://dx.doi.org/ 10.1002/ar.1091960210.
72. Everts V, Delaissé JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 2002; 17:77-90; PMID:11771672; http://dx.doi.org/10.1359/jbmr.2002.17.1.77.
73. Luiz de Freitas PH, Li M, Ninomiya T, Nakamura M, Ubaidus S, Oda K, et al. Intermittent PTH administration stimulates pre-osteoblastic proliferation without leading to enhanced bone formation in osteoclastless c-fos-/- mice. J Bone Miner Res 2009; 24:1586-97; PMID:19419301; http://dx.doi.org/10.1359/jbmr. 090413.
74. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008; 473:201-9; PMID:18406338; http://dx.doi.org/10.1016/j.abb.2008.03. 027.
75. Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011; 17:1473-80; PMID:22019888; http://dx.doi.org/10.1038/nm.2489.
76. Okamoto M, Murai J, Imai Y, Ikegami D, Kamiya N, Kato S, et al. Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. J Bone Miner Res 2011; 26:2511-22; PMID:21786321; http://dx.doi.org/10.1002/jbmr. 477.
77. Kwan Tat S, Pelletier JP, Amiable N, Boileau C, Lajeunesse D, Duval N, et al. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts. Arthritis Rheum 2008; 58:3820-30; PMID:19035475; http://dx.doi.org/10.1002/art.24029.
78. Kitamura T, Kabuyama Y, Kamataki A, Homma MK, Kobayashi H, Aota S, et al. Enhancement of lymphocyte migration and cytokine production by ephrinB1 system in rheumatoid arthritis. Am J Physiol Cell Physiol 2008; 294:C189-96; PMID:17942634; http://dx.doi.org/10.1152/ajpcell.00314.2007.
79. Romanovsky AA, Ivanov AI, Petersen SR. Microsomal prostaglandin E synthase-1, ephrins, and ephrin kinases as suspected therapeutic targets in arthritis: exposed by "criminal profiling". Ann N Y Acad Sci 2006; 1069:183-94; PMID:16855145; http://dx.doi.org/10.1196/annals.1351.016.
80. Edwards CM, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone 2008; 42:1007-13; PMID:18406675; http://dx.doi.org/10. 1016/j.bone.2008.01.027.
81. Roodman GD. Osteoblast function in myeloma. Bone 2011; 48:135-40; PMID:20601285; http://dx.doi.org/10.1016/j.bone.2010.06.016.
82. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD Jr., Barlogie B, et al. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood 2009; 114:1803-12; PMID:19597185; http://dx.doi.org/10.1182/blood-2009-01- 201954.
83. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483-94; PMID:14695408; http://dx.doi.org/10.1056/NEJMoa030847.
84. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106:3160-5; PMID:16030194; http://dx.doi.org/10.1182/blood-2004-12- 4940.
85. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008; 112:196-207; PMID:18305214; http://dx.doi.org/10.1182/blood-2008-01-132134.
86. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 2010; 107:5124-9; PMID:20194748; http://dx.doi.org/10.1073/pnas.0911929107.
87. Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 2009; 69:3736-45; PMID:19366806; http://dx.doi.org/10.1158/0008-5472.CAN-08-3232.
88. Fritsche-Guenther R, Noske A, Ungethüm U, Kuban RJ, Schlag PM, Tunn PU, et al. De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology 2010; 57:836-50; PMID:21166698; http://dx.doi.org/10.1111/j.1365-2559.2010.03713.x.
89. Varelias A, Koblar SA, Cowled PA, Carter CD, Clayer M. Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis. Cancer 2002; 95:862-9; PMID:12209731; http://dx.doi.org/10.1002/cncr. 10749.
90. Abdou AG, Abd el-Wahed MM, Asaad NY, Samaka RM, Abdallaha R. Ephrin A4 expression in osteosarcoma, impact on prognosis, and patient outcome. Indian J Cancer 2010; 47:46-52; PMID:20071790; http://dx.doi.org/10.4103/0019-509X.58859.
91. Kalinski T, Röpke A, Sel S, Kouznetsova I, Röpke M, Roessner A. Down-regulation of ephrin-A5, a gene product of normal cartilage, in chondrosarcoma. Hum Pathol. 2009; 40:1679-85; PMID: 19695673; http://dx.doi.org/10.1016/j.humpath.2009.03.024
92. Martin TJ, Allan EH, Ho PW, Gooi JH, Quinn JM, Gillespie MT, et al. Communication between ephrinB2 and EphB4 within the osteoblast lineage. Adv Exp Med Biol 2010; 658:51-60; PMID:19950015; http://dx.doi.org/10.1007/978-1-4419- 1050-9-6.
93. Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature 2012; 481:314-20; PMID:22258610; http://dx.doi.org/10.1038/ nature10763.